Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever?

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 441-443

  Takada, Ayato ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

antibody therapy; Ebola virus; envelope glycoprotein; filovirus; Marburg virus; nonhuman primates; passive immunization; virus neutralization

Indexed keywords

EBOLA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

CATALYSIS; COMPETITIVE INHIBITION; CONVALESCENCE; DISEASE SEVERITY; DISULFIDE BOND; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HYDROPHOBICITY; IMMUNOTHERAPY; INFLUENZA VIRUS A; MARBURG VIRUS; PASSIVE IMMUNIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; SEROLOGY; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE;

EID: 84877254434     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.29     Document Type: Review

References (20)

1. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454(7201), 177-182 (2008).
2. Dias JM, Kuehne AI, Abelson DM et al. A shared structural solution for neutralizing Ebola viruses. Nat. Struct. Mol. Biol. 18(12), 1424-1427 (2011).
3. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401(2), 228-235 (2010).
4. Matsuno K, Takada A. Antibody therapy as a future treatment option for Ebola virus infection. Future Virol. 2(6), 607-614 (2007).
5. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and post exposure prophylaxis of Ebola virus infection in an animal model by passivetransfer of a neutralizing human antibody. J. Virol. 76(12), 6408-6412 (2002).
6. Oswald WB, Geisbert TW, Davis KJ et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3(1), e9 (2007).
7. Marzi A, Yoshida R, Miyamoto H et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7(4), e36192 (2012).
8. Qiu X, Audet J, Wong G et al. Successful treatment of ebolavirus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4(138), 138-81 (2012).
9. Olinger GG Jr, Pettitt J, Kim D et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl Acad. Sci. USA 109(44), 18030-18035 (2012).
10. Dye JM, Herbert AS, Kuehne AI et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl Acad. Sci. USA 109(13), 5034-5039 (2012).
11. Marzi A, Engelmann F, Feldmann F et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110(5), 1893-1898 (2013).
12. Wong G, Richardson JS, Pillet S et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 4(158), 158-146 (2012).
13. Kajihara M, Marzi A, Nakayama E et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 86(24), 13467-13474 (2012).
14. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77(13), 7539-7544 (2003).
15. Nakayama E, Tomabechi D, Matsuno K et al. Antibody-dependent enhancement of Marburg virus infection. J. Infect. Dis. 204(Suppl. 3), S978-S985 (2011).
16. Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y. Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. 196(Suppl. 2), S347-S356 (2007).
17. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl Acad. Sci. USA 93(8), 3602-3607 (1996).
18. Dolnik O, Volchkova V, Garten W et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 23(10), 2175-2184 (2004).
19. Nakayama E, Yokoyama A, Miyamoto H et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin. Vaccine Immunol. 17(11), 1723-1728 (2010).
20. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091), 183-186 (2012).